NCT06859762 · MediLink Therapeutics (Suzhou) Co., Ltd.
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
What this study is about
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
View original scientific description
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Informed of the study before the start of the study and voluntarily sign their name and date in the ICF
- Able and willing to comply with protocol visits and procedures
- Age≥ 18 years
- ECOG PS of 0 or 1
- Tumor types as below: For Part 1 and Part 2: Pathologically confirmed diagnosis of an advanced solid tumor. For Part 3 (Histologically or cytologically confirmed diagnosis+ locally advanced unresectable or metastatic disease)
- Adequate organ and bone marrow function.
- Have at least 1 extracranial measurable tumor lesion.
- Adequate archival formalin-fixed paraffin embedded （FFPE） tissue from prior biopsy.
Exclusion criteria
- Prior treatment with an agent targeting CDH17
- Prior discontinuation of a topoisomerase I inhibitor due to treatment-related toxicities.
- Have received an ADC consisting of a topoisomerase I inhibitor.
- Concurrent enrollment in another clinical study, unless it is an observational clinical study.
- Inadequate washout period for prior anticancer treatment before the first dose of study drug
- Undergone major surgery within 4 weeks before the first dose of study drug or expect major surgery during the study.
- Received long term systemic steroids or other immunosuppressive therapy within 2 weeks before the first dose of study drug.
- Received any live vaccine within 4 weeks before the first dose of study drug or intend to receive a live vaccine during the study.
- Diagnosis or evidence of spinal cord compression or leptomeningeal carcinomatosis.
- Uncontrolled or clinically significant cardiovascular and cerebrovascular diseases.
- A history of non-infectious interstitial lung disease (ILD)/pneumonitis that requires steroids, current active ILD/pneumonitis.
- Have clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses.
- Uncontrolled third-space fluid that requires repeated drainage.
- Digestive system disease that may cause bleeding, perforation, jaundice, gastrointestinal obstruction.
- An active tuberculosis based on medical history.
- Known human immunodeficiency virus (HIV) infection.
- Active hepatitis C infection.
Where
- Phoenix, Arizona
- Santa Monica, California
- New Haven, Connecticut
- Kansas City, Kansas
- Baltimore, Maryland
- Detroit, Michigan
- New York, New York
- Durham, North Carolina
- Cincinnati, Ohio
- Cleveland, Ohio
- Houston, Texas
- San Antonio, Texas
And 1 more location — see the full list below.
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jan 14, 2026 · Source of record for eligibility and locations